Navigation Links
iPierian Appoints Dr. Chad Cowan and Dr. Konrad Hochedlinger to Scientific Advisory Board
Date:8/6/2009

SOUTH SAN FRANCISCO, Calif., Aug. 6 /PRNewswire/ -- iPierian, Inc., a biopharmaceutical company focused on changing the paradigm of drug discovery and development through the application of cellular reprogramming, today announced the appointments of Dr. Chad Cowan and Dr. Konrad Hochedlinger to the company's Scientific Advisory Board (SAB).

"Drs. Cowan and Hochedlinger are leading scientists in stem cell research and their addition to the iPierian SAB rounds out an exemplary group of scientists. The collective expertise of this SAB will further our efforts of developing disease-relevant models to discover drugs, and translating these efforts into new therapies for patients," said John P. Walker, chief executive officer of iPierian.

Dr. Chad Cowan is assistant professor of Medicine at Harvard Medical School and the Department of Stem Cell and Regenerative Biology, and assistant investigator at Stowers Medical Institute. His research focuses on adipogenesis, metabolic disease, and the impact of environmental and genetic factors on the development of disease.

Dr. Konrad Hochedlinger is assistant professor of Medicine at Harvard Medical School and the Department of Stem Cell and Regenerative Biology, principal faculty member at the Harvard Stem Cell Institute and investigator at the Massachusetts General Hospital Cancer Center and Center for Regenerative Medicine. Dr. Hochedlinger is a leader in reprogramming technology and produced the first transgene-free induced pluripotent stem (iPS) cells. Most recently, Dr. Hochedlinger received the International Society for Stem Cell Research (ISSCR) Outstanding Young Investigator Award.

About iPierian

iPierian is a South San Francisco-based biopharmaceutical company focused on the industrialization of induced pluripotent stem cell (iPS) technology with the mission of creating new therapeutics through cellular reprogramming and directed differentiation of patient cells. iPierian is backed by Kleiner Perkins Caufield & Byers, Highland Capital Partners, MPM Capital and FinTech Global Capital. The initial focus of the company is in neurodegeneration, particularly spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) and Parkinson's disease as well as in cardiovascular disease, where iPierian has a collaboration with The Gladstone Institute of Cardiovascular Disease and Dr. Deepak Srivastava, the institute's director. iPierian plans to enhance its partnership efforts to further expand into metabolic diseases. Earlier this year, the company announced a formal collaboration with the laboratory of Dr. Shinya Yamanaka of Kyoto University to develop and improve methods of deriving iPS cell lines in order to advance iPS cell technology.

Because iPS cells are believed to be able to grow indefinitely in culture and to differentiate into many cell types, iPS cells have great potential for disease research, preclinical drug testing and cell-based therapy. iPierian's approach places the patient at the forefront of the drug discovery process in order to reduce drug development time and increase the probability of success for drug candidates. iPierian plans to use precise human disease models to find new molecular targets and develop proprietary therapeutic small molecule or biologic drugs for its own pipeline to treat specific diseases.


'/>"/>
SOURCE iPierian, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Streamline Health Appoints Jon Phillips Chairman of the Board of Directors
2. Novo Nordisk Appoints Per Falk, M.D., Ph.D., as Vice President for Clinical, Medical and Regulatory Affairs for North America
3. Excaliard Pharmaceuticals Appoints Jay Birnbaum, Ph.D. to the Board of Directors.
4. Globaltel Media Appoints Leading Healthcare Industry Veterans to Advisory Board
5. Sunesis Pharmaceuticals Appoints Helen S. Kim to Board of Directors
6. Red Cross Appoints Peggy Dyer as Chief Marketing Officer
7. MonoSol Rx Appoints Theodore Clemente Vice President Business Development
8. WuXi PharmaTech Appoints Dr. Chi-Chung Chan as Vice President of Pharmacology
9. Webmedx Appoints New Senior Vice President of Client Development, Chris Cashwell
10. Immucor Appoints Chief Operating Officer
11. DaVita Clinical Research Appoints Mahesh Krishnan as Vice President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2017)... ... 2017 , ... The Pennsylvania Athletic Trainers’ Society’s (PATS) Annual ... Convention Center on June 8-10. The weekend consisted of many educational presentations, ... scholarship presentations, and professional networking. , On Friday June 9th, PATS hosted ...
(Date:6/23/2017)... ... 2017 , ... The Rhode Island Quality Institute (RIQI) and ... Dashboards, an innovative new service enabling healthcare providers to proactively coordinate care and ... Dashboards provide near real-time data about patients admitted to and/or discharged from acute ...
(Date:6/23/2017)... ... ... Studies show evidence that carotenoids and antioxidants derived either from the diet or from ... how often do ophthalmologists and optometrists in Sweden recommend the use of nutritional supplements, ... symptoms of AMD? A study published recently in Dove Medical Press journal, ...
(Date:6/23/2017)... ... June 23, 2017 , ... Everybody has their own personal preference when ... read it, and some people don't like it at all. FindaTopDoc took a look ... , Erotic literature can give readers a taste of their deepest, darkest fantasies and ...
(Date:6/23/2017)... ... June 23, 2017 , ... Georgia State ... 18 to 20. , The two-day conference is focused on advancing scientific knowledge ... improving patients’ lives and eliminating racial breast cancer-related disparities. The conference theme is ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... 8, 2017  StatLab Medical Products ("StatLab" ... manufacturer of diagnostic supplies for the anatomic ... & Company LP ("Cressey & Company"), a ... growth-focused investment in the Company. Cressey & ... from selling shareholder, Prairie Capital, L.P., with ...
(Date:6/7/2017)... , June 7, 2017  Novavax, Inc., (Nasdaq: ... two Phase 2 trials of its RSV F protein recombinant ... bearing age have been published in the journal ... been shared in prior scientific conferences). The Company previously announced ... 2014. Novavax is developing the RSV F Vaccine with the ...
(Date:6/5/2017)... , June 5, 2017 The ... brand of Diplomat Pharmacy, Inc. (NYSE: DPLO), has been awarded ... Cincinnati Enquirer . Results are based on an ... in organizational health and workplace improvement. The survey measures several ... ...
Breaking Medicine Technology: